Rivastigmine

Rivastigmine is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's.

Rivastigmine

Rivastigmine; 123441-03-2; Exelon; ENA 713 free base; Prometax

Exelon, Exelon Patch, Rivadem, Rivamer, Rivasmine, Rivasun, Rivera, Zeemine

3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate

Rivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor.

The starting dose is 1.5 mg twice a day (BID).

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Accidental trauma, fatigue, asthenia, dizziness, headache, somnolence, agitation, insomnia, confusion, depression, nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, dyspepsia, upper respiratory tract infection, urinary tract infection.

• May exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia.
• Tobacco smoking may increase its clearance.
• Food delays absorption

• Hypersensitivity to other carbamate derivatives.
• Severe hepatic impairment.

Store below 25°C

Molecular weight

250.3367

Molecular formula

C14H22N2O2

CAS number

123441-03-2

Precautions

• Cholinergic stimulation may increase gastric acid secretion.
• May exacerbate urinary obstruction and seizures.
• Pregnancy.
• Renal impairment, mild to moderate hepatic impairment.
• Monitor body wt.
• Asthma or obstructive pulmonary disease.
• May worsen extra pyramidal symptoms.
• Lactation.